header logo image


Page 362«..1020..361362363364..370380..»

We Analyzed the Future Direction of Vir Biotechnology Inc. (VIR), Here is What We Found – The News Heater

October 4th, 2020 11:00 am

Vir Biotechnology Inc. (NASDAQ:VIR) went down by -9.01% from its latest closing price compared to the recent 1-year high of $75.00. The companys stock price has collected 2.69% of gains in the last five trading sessions. Press Release reported on 09/24/20 that Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell

Opinions of the stock are interesting as 4 analysts out of 7 who provided ratings for Vir Biotechnology Inc. declared the stock was a buy, while 0 rated the stock as overweight, 2 rated it as hold, and 0 as sell.

The average price from analysts is $50.67, which is $17.34 above the current price. VIR currently public float of 109.06M and currently shorts hold a 4.67% ratio of that float. Today, the average trading volume of VIR was 1.18M shares.

VIR stocks went up by 2.69% for the week, with a monthly drop of -15.19% and a quarterly performance of -13.31%. The volatility ratio for the week stands at 9.00% while the volatility levels for the past 30 days are set at 10.19% for Vir Biotechnology Inc.. The simple moving average for the period of the last 20 days is 6.75% for VIR stocks with a simple moving average of 3.21% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with Goldman repeating the rating for VIR by listing it as a Buy. The predicted price for VIR in the upcoming period, according to Goldman is $54 based on the research report published on September 14th of the current year 2020.

JP Morgan, on the other hand, stated in their research note that they expect to see VIR reach a price target of $29. The rating they have provided for VIR stocks is Neutral according to the report published on September 11th, 2020.

Needham gave a rating of Buy to VIR, setting the target price at $62 in the report published on August 20th of the current year.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.23% of loss for the given period.

Volatility was left at 10.19%, however, over the last 30 days, the volatility rate increased by 9.00%, as shares surge +1.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.16% lower at present.

During the last 5 trading sessions, VIR rose by +2.69%, which changed the moving average for the period of 200-days by +151.32% in comparison to the 20-day moving average, which settled at $32.18. In addition, Vir Biotechnology Inc. saw 173.00% in overturn over a single year, with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at VIR starting from Virgin Herbert, who sale 3,805 shares at the price of $31.71 back on Sep 22. After this action, Virgin Herbert now owns 20,000 shares of Vir Biotechnology Inc., valued at $120,638 using the latest closing price.

Pang Phillip, the Chief Medical Officer of Vir Biotechnology Inc., sale 12,500 shares at $31.90 during a trade that took place back on Sep 16, which means that Pang Phillip is holding 29,777 shares at $398,694 based on the most recent closing price.

Current profitability levels for the company are sitting at:

The net margin for Vir Biotechnology Inc. stands at -2158.98. The total capital return value is set at -62.52, while invested capital returns managed to touch -62.97. Equity return is now at value -81.10, with -42.30 for asset returns.

Based on Vir Biotechnology Inc. (VIR), the companys capital structure generated 0.27 points at debt to equity in total, while total debt to capital is 0.27. Total debt to assets is 0.22, with long-term debt to equity ratio resting at 0.21. Finally, the long-term debt to capital ratio is 0.21.

When we switch over and look at the enterrpise to sales, we see a ratio of 119.29, with the companys debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.81.

Read more:
We Analyzed the Future Direction of Vir Biotechnology Inc. (VIR), Here is What We Found - The News Heater

Read More...

Is Abeona Therapeutics Inc (ABEO) The Right Choice in Biotechnology? – InvestorsObserver

October 4th, 2020 11:00 am

A rating of 34 puts Abeona Therapeutics Inc (ABEO) near the middle of the Biotechnology industry according to InvestorsObserver. Abeona Therapeutics Inc's score of 34 means it scores higher than 34% of stocks in the industry. Abeona Therapeutics Inc also received an overall rating of 40, putting it above 40% of all stocks. Biotechnology is ranked 27 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Abeona Therapeutics Inc (ABEO) stock is unmoved -0.48% while the S&P 500 is lower by -1.28% as of 11:06 AM on Friday, Oct 2. ABEO is flat $0.00 from the previous closing price of $1.05 on volume of 1,099,195 shares. Over the past year the S&P 500 has gained 14.67% while ABEO is lower by -53.54%. ABEO lost -$1.31 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

Excerpt from:
Is Abeona Therapeutics Inc (ABEO) The Right Choice in Biotechnology? - InvestorsObserver

Read More...

Global Regenerative Medicine Partnering Report 2014-2020: Access to Cell Therapy, Organ Regeneration, Stem Cells and Tissue Regeneration Partnering…

October 4th, 2020 10:57 am

DUBLIN, Sept. 30, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1100 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.

Key benefits

Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

In Global Regenerative Medicine Partnering Terms and Agreements 2014-2020, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking2.1. Introduction2.2. Regenerative Medicine partnering over the years2.3. Most active Regenerative Medicine dealmakers2.4. Regenerative Medicine partnering by deal type2.5. Regenerative Medicine partnering by therapy area2.6. Deal terms for Regenerative Medicine partnering2.6.1 Regenerative Medicine partnering headline values2.6.2 Regenerative Medicine deal upfront payments72.6.3 Regenerative Medicine deal milestone payments2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals3.1. Introduction3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers4.1. Introduction4.2. Most active Regenerative Medicine dealmakers4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory5.1. Introduction5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmaking

AppendicesAppendix 1 - Regenerative Medicine deals by company A-ZAppendix 2 - Regenerative Medicine deals by stage of developmentAppendix 3 - Regenerative Medicine deals by deal typeAppendix 4 - Regenerative Medicine deals by therapy area

For more information about this report visit https://www.researchandmarkets.com/r/dcq9uu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View original post here:
Global Regenerative Medicine Partnering Report 2014-2020: Access to Cell Therapy, Organ Regeneration, Stem Cells and Tissue Regeneration Partnering...

Read More...

3 new degrees approved, including Ph.D. in regenerative medicine – IU Newsroom

October 4th, 2020 10:57 am

The Indiana University Board of Trustees has approved three new degrees, including a doctorate in the medical field and a master's in the accounting field.

During its meeting Oct. 1, the trustees supported three proposed degrees:

Regenerative medicine is a field that involves replacing or regenerating human cells, tissues or organs to establish, restore or enhance normal function.

The Ph.D. program in regenerative medicine and technologies will be offered by the Indiana Center for Regenerative Medicine and Engineering and the Department of Surgery at the IU School of Medicine. The program, open to practicing medical doctors, will provide an avenue for cutting-edge research that can be used in new ways to treat patients.

Before this approval, IU had no graduate-level programs for students seeking a degree in regenerative medicine and technologies. The labor market demand for such graduates is considered strong, with jobs in biotechnology companies, academic laboratories, and medical device manufacturing and logistics companies.

Changes in the accounting field and large employers' expressed needs have prompted the development of a new Master of Science in accounting curriculum that will prepare students for the emerging data-focused professional services workplace. With the proliferation of data and analytics techniques applications in the business world, integrated accounting, data and analytics competencies are required for the best job placements.

The new Master of Science in accounting with data and analytics degree will be offered by the Kelley School of Business. It will replace the current, traditional Master of Science in accounting degree as the residential offering on the Bloomington campus. The traditional Master of Science in accounting will continue to be offered through the Kelley School's online programs and will target "career switchers."

Students who seek the flexibility of an online format, have an interest in studying the foundations of sustainability and want to apply that knowledge to complex socio-environmental problems can find that opportunity in a new offering at IU Northwest, through the College of Arts and Sciences. The Bachelor of Arts in sustainability studies is a collaborative online degree, and was previously approved at IUPUI, IU East, IU Kokomo, IU South Bend and IU Southeast.

Regional demand for energy and sustainability specialists and the demand for "green" jobs are expected to grow over the next 10 years. Graduates with the degree could find jobs such as an energy analyst, environmental health and safety specialist, or an occupational health and safety technician.

The degrees approved by IU's trustees still await final approval by the Indiana Commission for Higher Education.

Read the rest here:
3 new degrees approved, including Ph.D. in regenerative medicine - IU Newsroom

Read More...

Global Regenerative Medicine Market 2020 Growth Analysis, Trends, COVID-19 Analysis and Forecast to 2024, Key Manufacturers- Novartis AG, Medtronic…

October 4th, 2020 10:57 am

Aimed at offering Global Regenerative Medicine Market: Size and Forecast with Impact Analysis of COVID-19 (2020-2024) report readers with updated information as well as market relevant cues to leverage uninhibited growth in the Global Regenerative Medicine market, this intricately researched, designed, and articulated real-time reference of the market is a culmination of in-depth research mettle and best in class primary and secondary research initiatives that collectively influence a favorable growth trajectory in the Global Regenerative Medicine market.

In continuation with all the above market specific information furnished above, the report further in its subsequent sections also throws light upon other additional yet pertinent details that further channelize revenue generation in the Global Regenerative Medicine market. The report highlights massively the core growth propellants such as market driving factors, prevailing challenges and the like that tend to have a negative growth impact on the global Global Regenerative Medicine market.

Request a sample of Global Regenerative Medicine Market report @ https://www.orbisresearch.com/contacts/request-sample/4707408

Key Manufacturers Analysis:

Novartis AGMedtronic PlcBristol Myers Squibb (Celgene Corporation)Smith+Nephew (Osiris Therapeutics, Inc.)

Global Regenerative Medicine market Segmentation by Type:

Type IType IIType III

Global Regenerative Medicine market Segmentation by Application:

Application IApplication IIApplication III

Access full report @ https://www.orbisresearch.com/reports/index/global-regenerative-medicine-market-size-and-forecast-with-impact-analysis-of-covid-19-2020-2024

Various other dynamics of the Global Regenerative Medicine market pertaining to the growth prospects have been mentioned and well elaborated in the course of the report documentation thus ushering a novel perspective for the players to instrument growth propelling business decisions, defying stringent competition in the Global Regenerative Medicine market. Based on a thorough analytical review leading players comprising both established and new market aspirants in the Global Regenerative Medicine market can have a thorough understanding about the market and subsequently chalk out elaborate plans to steer remunerative returns in the aforementioned Global Regenerative Medicine market.

Key Regions:

North AmericaEuropeAsia PacificROW

All the mentioned updates about the Global Regenerative Medicine market specified in the report have been derived post a dedicated research initiative comprising primary and secondary research practices. Proceeding into unraveling new developments in the report pertaining to the Global Regenerative Medicine market, the report is committed to offer a decisive, problem solving approach based on which readers are encouraged to unravel the various discerning factors and inputs that collectively orchestrate an optimistic growth trail in the discussed Global Regenerative Medicine market.

Ready-to refer Market Insider Reports: Top Reason to Buy the Report

1. A team of expert research veterans, practicing best in industry roles to derive real time developments in the Global Regenerative Medicine market, affecting growth.2. Systematic segment-wise analysis to identify growth reckoning segment.3. A thorough historical study to decode future growth trajectory.4. Rear view analysis of opportunity landscape and barrier analysis and threat identification.5. Astute analysis of the competition spectrum to identify market leaders and their growth favoring business tactics.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4707408

ABOUT US:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

CONTACT US:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Excerpt from:
Global Regenerative Medicine Market 2020 Growth Analysis, Trends, COVID-19 Analysis and Forecast to 2024, Key Manufacturers- Novartis AG, Medtronic...

Read More...

Remember how urgent it was to support embryonic stem cell research? That was then; this is now – BioEdge

October 4th, 2020 10:57 am

Remember how urgent it was to support embryonic stem cell research? That was then; this is now

The hot button bioethical issue of 2004 was embryonic stem cell research. Supporters spoke of life-saving cures and dismissed ethical misgivings. Surfing a wave of hope, Californian voters voted for a US$3 billion bond issue to establish the California Institute for Regenerative Medicine.

Sixteen years later, the CIRM has almost run out of money and its backers are rattling the tin in the hope that voters will approve a $5.5 billion bond issue to support its research.

Some of the states major newspapers have editorialised against it. With many of its critics, they contend that the CIRM has not delivered on its miracle cures, that its governance has been poor and that there was too much potential for conflict of interest.

The Los Angeles Times decried the earlier over-sell:

[The CIRM] hasnt yet yielded a significant financial return on investment for the state or the cures that were ballyhooed at the time. Though no one ever promised quick medical miracles, campaign ads strongly implied they were around the corner if only the funding came through. Proponents oversold the initiatives and voters cant be blamed if they view this new proposal with skepticism.

The San Francisco Chronicle, which exposed some of the CIRMs deficiencies in a 2018 expos, criticised the way its funds had been spent:

More than half the original funding went to buildings and other infrastructure, education and training, and the sort of basic research that, while scientifically valuable, is a long way from medical application. Theres nothing inherently wrong with that, but it is at odds with the vision of dramatic advancements put to voters."

Michael Cook is editor of BioEdge

Read the rest here:
Remember how urgent it was to support embryonic stem cell research? That was then; this is now - BioEdge

Read More...

What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) – KQED

October 4th, 2020 10:57 am

Olivia Allen-Price [00:01:55] OK, so what exactly does this bond fund?

Danielle Venton [00:01:59] This would fund $5.5 billion in stem cell research and treatments in California. Some of the diseases that stem cell research is seeking to cure or treat include cancer, Alzheimer's disease, diabetes, spinal cord injuries, blindness, and even COVID-19. I spoke recently with a guy named Jake Javier. He supports this bond initiative because he knows firsthand how life changing stem cell research can be.

Jake Javier [00:02:25] I am in my last year at Cal Poly.

Danielle Venton [00:02:28] So, Jake grew up locally in Danville and was just graduating high school when he suffered a life altering injury.

Jake Javier [00:02:35] On the last day of high school, I drove in to a pool and hit my head on the bottom and broke my neck and was immediately paralyzed.

Danielle Venton [00:02:47] He says his injury was complete, with very little hope of recovery. But a doctor at Stanford reached out to Jake and his family and said, you can be part of this clinical trial where we, with a one time surgery, will inject stem cells into the damaged area and you may possibly see some benefits.

Danielle Venton [00:03:07] Now, Jake is still injured.

Jake Javier [00:03:09] I'm a quadriplegic. I use a wheelchair.

Danielle Venton [00:03:11] But he says after the surgery, he noticed more movement in his arms, in his hands.

Jake Javier [00:03:17] So, I mean, with my injury, I'm at a level where I would normally not have any function at all in my hands and very, very little function like in my triceps and things like that. Muscles that are really important for functionality and, you know, being able to get through day to day activities that could help me push myself around more, help me transfer in and out of my chair independently. And then also, I notice, you know, I got some some finger movement. It doesn't seem like much, but even that little movement has helped me so much with picking things up and things like that. So it was really, I was really blessed to see that happen.

Danielle Venton [00:03:51] So he doesn't know how much of his recovery is due to the stem cells. How much is natural, or how much is due to physical therapy. But today he's able to live independently, to go to college and he wants to pursue a career in medicine. And he is a big believer in stem cell research, regenerative medicine, and is really hoping that California voters will support this proposition.

Olivia Allen-Price [00:04:20] Now, what exactly are stem cells and how do they work, I guess?

Danielle Venton [00:04:25] Yeah, stem cells are types of cells that can be turned into any type of specialized cell. Scientists have known about them since the eighteen hundreds, but it wasn't until the late 90s that researchers developed a method to derive them from human embryos and grow them in a laboratory. And then people really began to get excited about their potential for medicine. Now these cells came from unused embryos created for in vitro fertilization, and they were donated with informed consent. But many anti-abortion groups felt that using the cells were tantamount to taking a human life. So in 2001, then President George W. Bush banned federal funding for any research using newly created stem cell lines.

Olivia Allen-Price [00:05:09] OK. And how does that get us now to bonds in California?

Danielle Venton [00:05:13] Well, Californians wanted to circumvent these federal restrictions, and in 2004 voted for a bond that gave the state $3 billion to create a research agency called the California Institute of Regenerative Medicine, or CIRM. There was a lot of public support for it. And it just felt like these wonderful cures could be right around the corner. Celebrities like Michael J. Fox appeared in TV commercials.

Michael J. Fox TV commercial [00:05:36] My most important role lately is as an advocate for patients, and for finding new cures for diseases. That's why I'm asking you to vote yes on Proposition 71, Stem Cell Research Initiative.

Danielle Venton [00:05:48] And the money for that research, that $3 billion, has now run out. And to continue their work, the stem cell advocacy group, Americans for Cures, is asking voters for more money.

Olivia Allen-Price [00:06:00] So we're basically voting on whether we want to refill the stem cell research piggy bank here.

Danielle Venton [00:06:05] Yeah, exactly. Some question if the state can afford this at this time when budgets are going to be so tight. Others have been disappointed by the slow pace of cures coming out of the field. Now, there are people who credit this research, such as Jake, with improving or restoring their health or the health of their loved ones. Or maybe they hope that one day it will, and they would balk at the idea that this is not worthy research. They point to achievements that the agency has funded. That includes effectively a cure for bubble baby disease. This is when someone is born without a functioning immune system. That mutation can now be corrected with genetically modified stem cells. And recently, just within the last year or so, the FDA approved two new treatments for blood cancer, developed with CIRM support. These achievements are what the agency points to when they're criticized for not having accomplished more. And they say the process of scientific discovery is long and unpredictable.

Olivia Allen-Price [00:07:04] Now, wasn't that Bush-era ban on stem cell research that you were talking about earlier wasn't that overturned?

Danielle Venton [00:07:11] Yes, that was overturned by President Obama. However, there are current members of Congress who are lobbying President Trump to ban the research again. And if that happens, then California would be the only major player in stemcell research once again in the United States.

Olivia Allen-Price [00:07:30] All right, so who is supporting Prop 14?

Danielle Venton [00:07:32] Governor Gavin Newsom, for one. Many patient advocacy organizations and medical and research institutions, including the California Board of Regents. These people don't want to see the pace of this research slow. They want it to accelerate. The political action committee supporting this proposition is reporting more than six million dollars in contributions.

Olivia Allen-Price [00:07:53] All right. And what about the opposition? Who's against it?

Danielle Venton [00:07:55] Well, so far, there's no organized, funded opposition. There have been several newspaper editorials coming out against it, including locally, the Mercury News and the Santa Rosa Press Democrat. They basically say state bonds aren't the way to fund research and the situation isn't like it was in 2004 and that the institute should now seek other sources of funding and move forward as a nonprofit.

Olivia Allen-Price [00:08:19] All right, Danielle. Well, thanks, as always for your help.

Danielle Venton [00:08:21] My pleasure. Thanks.

Olivia Allen-Price [00:08:28] In a nutshell, a vote yes on Proposition 14 says you think Californians should give $5.5 billion to the state's stem cell research institute. That money will be raised by selling bonds, which the state would pay back, with interest, out ofthe general fund over the next 30 years. A vote no means you think we shouldn't spend public money on this research.

Olivia Allen-Price [00:08:54] That's it on Proposition 14. We'll be back tomorrow with an episode on Prop 15. And oh, it is a doozy. Commercial property tax! A partial rollback of one of California's most controversial propositions! It's going to be fire. In the meantime, you can find more of KQED election coverage at KQED.org/elections. Two reminders on the way out: October 19th is the last day to register to vote and mail in ballots must be postmarked on or before November 3rd.

Olivia Allen-Price [00:09:28] Bay Curious is made in San Francisco at member supported KQED. I'm Olivia Allen-Price. See you tomorrow.

Follow this link:
What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) - KQED

Read More...

Regenerative Medicine Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 – The Daily Chronicle

October 4th, 2020 10:57 am

Fort Collins, Colorado The Regenerative Medicine Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The Regenerative Medicine Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the Regenerative Medicine Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global Regenerative Medicine Market valued approximately USD 49.68 billion in 2018 is anticipated to grow with a healthy growth rate of more than 24.2% over the forecast period 2019-2026.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=28424

Industry Regenerative Medicine Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=28424

The report provides comprehensive data on the Regenerative Medicine market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The Regenerative Medicine Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the Regenerative Medicine market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

By Technology:

By Application:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=28424

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the Regenerative Medicine Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-regenerative-medicine-market-size-study/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

View original post here:
Regenerative Medicine Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

Read More...

Regenerative Medicine Market 2020: Analysis, Top Companies, Size, Share, Demand and Opportunity To 2025 – Crypto Daily

October 4th, 2020 10:57 am

According to IMARC Groups latest report, titled Regenerative Medicine Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,. Looking forward, IMARC Group expects the global regenerative medicine market to continue its strong growth during the next five years.

Regenerative medicine refers to a field of biomedical sciences involved in restoring the structure and function of damaged cells, organs, and tissues. It includes the study of stem cells that are developed in laboratories and then safely inserted into the human body to regenerate damaged bones, cartilage, blood vessels, and organs. Cellular and acellular regenerative medicines are widely adopted in various clinical therapeutic procedures, including cell therapies, immunomodulation, and tissue engineering. They have the potential to treat various chronic diseases, including Alzheimers, Parkinsons, cardiovascular disorders (CVDs), osteoporosis, spinal cord injuries, etc.

Request for a free sample copy of this report: https://www.imarcgroup.com/regenerative-medicine-market/requestsample

Market Trends

The rising prevalence of chronic diseases and genetic disorders is primarily driving the demand for regenerative medicine across the globe. Moreover, the growing geriatric population who are more prone to musculoskeletal, dermatological, and cardiological disorders is also augmenting the need for regenerative medicines. Furthermore, several technological advancements in cell-based therapies have led to the adoption of 3D bioprinting techniques and artificial intelligence (AI), thereby further propelling the market for regenerative medicine. Moreover, regenerative medicine decreases the risk of organ rejection by the body post-transplant and increases the patients recovery speed, thereby gaining traction in numerous organ transplantation procedures. The increasing investments in extensive R&D activities in the field of medical sciences are expected to drive the market for regenerative medicine.

Regenerative Medicine Market 2020-2025 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

The report has segmented the market on the basis of type, application, end user and region.

Breakup by Type:

Breakup by Application:

Breakup by End User:

Explore full report with table of contents: https://bit.ly/2RAf08Y

Breakup by Region:

Key highlights of the report:

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US:IMARC Group30 N Gould St, Ste RSheridan, WY 82801, USAWebsite: https://www.imarcgroup.com/Email: [emailprotected]USA: +1-631-791-1145Follow us on twitter: @imarcglobalLinkedin: https://www.linkedin.com/company/imarc-group

See the rest here:
Regenerative Medicine Market 2020: Analysis, Top Companies, Size, Share, Demand and Opportunity To 2025 - Crypto Daily

Read More...

FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin – Business Wire

October 4th, 2020 10:57 am

MIAMI--(BUSINESS WIRE)--Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19.

This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease. Aside from Convalescent Plasma, Zofin, is the first reported acellular therapy which can be accessed under FDAs approved expanded access program. Zofin is manufactured to retain naturally occurring microRNAs, without the addition of any other substance or diluent.

This recent FDA approval follows the treatment of six outpatients treated under emergency INDs, who have reported significant improvement after being treated with Zofin. Organicell is currently in the process of enrolling moderate to severe COVID-19 patients for a Phase I/II placebo controlled clinical trial (NCT04384445) to evaluate the safety and potential efficacy of Zofin.

Treating patients in an outpatient setting may be critical in helping to prevent the progression of the disease and further hospitalization which could lessen the impact on hospitals, thereby reducing medical costs, said Albert Mitrani, Chief Executive Officer of Organicell.

About Organicell Regenerative Medicine, Inc.:

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of nanoparticles to develop innovative biological therapeutics for the treatment of degenerative diseases. The companys proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Maria Ines Mitrani, Chief Science Officer. To learn more, please visit https://organicell.com/.

About Zofin:

Zofin is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin for the treatment of moderate to SARS related to COVID-19 infection vs placebo.

Forward-Looking Statements

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the Securities Act), the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as will, believes, expects, potential or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Visit link:
FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin - Business Wire

Read More...

FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration – PRNewswire

October 4th, 2020 10:57 am

HOUSTON, Oct. 1, 2020 /PRNewswire/ -- FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs has entered into a clinical collaboration agreement with Brazilian R4D Biotech.Holding the world's largest patent portfolio in the field of cell therapies using fibroblasts, FibroGenesis is expanding its ongoing clinical programs internationally. The partnership will pave the way for clinical studies of PneumoBlast in Brazil as a unique treatment of acute respiratory distress syndrome (ARDS) for patients affected by COVID-19, in parallel to clinical studies in the United States upon approval by the FDA.

Administration of PneumoBlast in pre-clinical and animal studies resulted in dramatic improvement of immunological signaling molecules, reducing concentrations of the inflammatory cytokines interleukin-1 beta, interleukin-6, interleukin-8, interleukin-17, interleukin-18, and Tumor Necrosis Factor alpha TNFa. Company scientists have also demonstrated that PneumoBlast has induced statistically significant reduction of lung fibrosis and lung scarring in COVID-19 infected animals, particularly when compared to more conventional treatments using bone marrow derived mesenchymal stem cells (BMSCs). Furthermore, recent data supports the potential benefits of PneumoBlast for preventing COVID-19 blood clotting. Both companies will collaborate on a clinical study design that meets the needs of Brazilian patients.

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against this virus," commented Pete O'Heeron, Chief Executive Officer, FibroGenesis. "The collaboration with R4D Biotech is another strategic milestone that emphasizes our commitment to expand fibroblast research globally."

"The lab results which indicate our cell therapy approach possesses both therapeutic effects on animal models of the acute stage of COVID-19, and also benefits a cure for residual pathology seen in COVID-19 patients, has our research team extremely excited," said Thomas Ichim, Ph.D., Chief Scientific Officer, FibroGenesis.

"Technology transfer is at the core of this partnership," said Paulo Ferraz, BRICS/Emerging Markets Director of international fund Newstar Ventures and an advisor for FibroGenesis on this transaction. "R4D Biotech has access to sophisticated resources comprising research facilities and hospitals, and its talent pool includes scientific advisors who are recognized academics and distinguished members of the Brazilian Academy of Pharmaceutical Sciences. PneumoBlast clinical study will represent the first step in a long-term relationship designed to aid in the discovery of advanced therapeutic solutions for chronic medical needs."

About R4D Biotech:R4D Biotech is a Brazilian emerging company headquartered in the state of So Paulo focused on research and development for biotechnology and healthcare, with the mission of bringing disruptive technology innovation across all steps of clinical development in life sciences.

About FibroGenesis:Based in Houston, Texas, FibroGenesis is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 240+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.Visit http://www.Fibro-Genesis.com.

SOURCE FibroGenesis

http://www.Fibro-Genesis.com

Read more:
FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration - PRNewswire

Read More...

Vitro Biopharma 3rd Quarter ended July 31st 2020 Financial Results of Operations – BioSpace

October 4th, 2020 10:57 am

GOLDEN, CO / ACCESSWIRE / October 1, 2020 / Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced its 3rd quarter, ended July 31st 2020, financial results of operations.

Vitro Biopharma recorded 3rd quarter revenues of $132,066 vs $225,191 a decrease of 41% over the comparative quarter last year. Revenues were up slightly from the prior quarter which were $128,631. The decrease in revenue is directly attributed to the COVID 19 pandemic. Lockdown extensions and business opening limitations have pushed our expectations of growth and revenue recovery out to the first half of 2021. Feedback from our customers and our partner clinic in the Cayman Islands http://www.DVCstem.com are that patients awaiting treatments are not dropping off, but merely postponing their treatments and as such, a significant backlog is building. The cosmetic clinics http://www.Infinivive.com have started to open up but only with lower occupancy and variations by state, resulting in reduced revenue into the 4th quarter with expectations of a revival of revenue into the first half of 2021.

Gross profit declined 3% from the comparative quarter last year primarily due to the reduced higher margin stem cell product sales versus the mid margin stem cell research and development products.

Overall operating expenses increased in the quarter ended July 31st 2020 by $180,326 to $336,442 from $194,682 in the prior year's comparative quarter. The increase in expenses reflects the increased costs of FDA regulatory, legal, consulting, and audit costs. We engaged the audit firm of MaloneBailey LLP to get the company fully reporting around January of 2021.

Vitro Biopharma Announces MaloneBailey L.L.P. as its new Auditors

The company added extra resources to turn its attention to the world-wide challenge of finding therapies to fight COVID-19. Vitro filed an Investigational New Drug ("IND") application and through its collaboration with GIOSTAR, received FDA authorization to treat COVID 19 patients under the Expanded Access Program with its AlloRx Stem Cells . A single patient was treated successfully with no adverse events and the patient showed evidence of improved lung, liver and kidney function while also recovering from a stroke-induced coma.

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®

The company entered into an MOU with GIOSTAR, a leading global stem cell research company, who operates multiple international stem cell clinics. The supply agreement provides GIOSTAR with the use of our AlloRx Stem Cells to treat COVID 19 patients through FDA-pre and post-market approval.

Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

During and subsequent to the quarter the company achieved and pursed the following objectives:

During the quarter and subsequent to the quarter, the company continued with its Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company has sold $1.0 million of the Series A Convertible Preferred Stock during and subsequent to the quarter. The offering was sold out at $1.0 million and the company has expanded it to a total of up to $3.5 million to ensure sufficient working capital during the Coronavirus pandemic and to start the regulatory process of current reporting audits and funding for its expanded clinical trial activities with the FDA.

As a part of our overall strategy to target both global and US stem cell markets, Vitro submitted a Phase I IND application to the FDA to assess the safety of AlloRx Stem Cells in the treatment of COVID-19. We have established strong communication channels with FDA officials to facilitate our IND review and are providing additional information to the FDA to complete the approval of our IND. Several clinical centers have expressed interest in our stem cell therapy and we continue to enlist multi-center sites to conduct our Phase 1 trial. We are also pursuing other avenues for emergency use under the Expanded Access Program. No adverse events were reported and the patient who had various comorbidities stabilized and exhibited enhanced pulmonary, liver and renal function during the six weeks following AlloRx Stem Cell Therapy. The patient has now recovered and is at home from the hospital after 3 months of intensive care. We are currently pursuing additional emergency use authorizations under expanded access provision applications through our collaboration with GIOSTAR. MSCs have been shown to block the cytokine storm that occurs in COVID-19 patients in acute respiratory distress through their powerful anti-inflammatory effects. The cytokine storm leads to the need for assisted breathing by ventilators, transfer to ICU and related burdens on the US health care system. It is important to note that AlloRx Stem Cells are a possible therapy for other viral attacks including influenza. Stem cells may block acute respiratory distress and may repair damage to other major organs including cardiovascular, pulmonary, hepatic and renal systems. AlloRx Stem Cells have been shown to assist in recovery from failure of various organ systems in COVID-19 survivors, as our case study and results from several other labs are demonstrating.

The Company entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. ("GIOSTAR") a leading stem cell research institute based in San Diego, California. GIOSTAR has filed for a separate IND application using Vitro Biopharma's umbilical cord mesenchymal stem cell product AlloRx Stem Cells in a clinical trial to treat COVID-19 patients. GIOSTAR has already obtained emergency use authorization under expanded access provisions from the FDA for severe COVID-19 hospitalized patients using AlloRx Stem Cells.

Vitro continues to seek FDA authorization of its pending IND. As the approval process proceeds, Vitro will seek AlloRx Stem Cells FDA approval through Phase 2/3 IND filings for other indications such as osteoarthritis while at the same time continuing to supply GIOSTAR AlloRx Stem Cells for treatment of COVID-19 patients in global markets.

The company has delayed the expansion of its laboratory and manufacturing facilities to better reflect the delays in revenue brought on by the pandemic. This new facility is expected to be operating in the second half of 2021. Our present facility has approximately $6M of AlloRx Stem Cell Vitro Biopharma revenue capacity per year. Furthermore, the completion of the 2nd clean room processing facility would expand our potential capacity to approximately 100 Billion AlloRx Stem Cell s a month or approximately $1.7 Million of AlloRx Stem Cell revenue capacity per month. This would give Vitro Biopharma a revenue run rate capacity of $20M a year.

Our increased capacity is rigorously controlled by our Quality Management System, now certified to the ISO9001 Quality Standard and the ISO13485 Medical Device Standard as well. This provides cGMP-compliant manufacturing of the highest quality stem cells/medical devices for clinical trial testing to provide further evidence of safety and efficacy for treatment of a wide variety of indications. Highly regulated cGMP biologics manufacturing within a BLA-compliant facility provides numerous opportunities to the Company to drive strong revenue growth. We are presently focused on our partnerships in the Caribbean with DVC Stem in Grand Cayman Island, InfiniVive MD in the US and emerging opportunities in the The Medical Pavilion of the Bahamas We are actively pursuing other partnership opportunities as well.

We have reformulated with our contract manufacturer to produce STEMulize in large quantity manufacturing runs. STEMulize contains natural substances that activate the body's own stem cells to enhance recovery from injury such as TBI, stroke, MS, PD and other autoimmune, inflammatory and neurological diseases. The STEMulize product will be offered as a private label product to Infinivive MD clinics and is being implemented as supplemental support to clinical treatments now ongoing in the Cayman Islands. Patients report positive benefits fromSTEMulize therapy following stem cell transplants including increased overall energy and enhancement of improved motor function in MS patients. We are currently pursing licensing arrangements with nutraceutical companies that can scale our formulation under their own private label.

The Company's cosmetic stem cell serum private labelled as Infinivive MD is being applied as a topical cosmetic serum in medical spas and plastic surgery offices. Infinivive MD revenue was reduced by the Coronavirus pandemic and as a result, revenues declined by 52% in the current quarter to approximately $50,000 vs $105,000 in the prior comparative quarter in 2019. This revenue has been flat from the prior quarter reflecting the reduced treatments due to the pandemic capacity limitations of various states.

Infinivive MD Cosmetic Serum is revolutionizing the cosmetic industry. Patients are experiencing unparalleled improvements in the appearance of fine lines and wrinkles. This is one of the fastest growing revenue streams for Vitro Biopharma.. We work with a variety of regulatory experts to assist us in the appropriate regulatory pathways.

http://www.jackzamoramd.com http://www.infinivivemd.com

Vitro Biopharma's OEM cosmetic topical serum is being distributed exclusively by Infinivive MD into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in a number of clinics throughout the United States and soon internationally,; but with the clinics just opening again for business and with limited occupancy rules we do not expect this revenue to recover back to peak levels with growth until the first half of 2021.

The company has brought on Dr. Jack Zamora as its chief medical officer (C.M.O.) and together we have developed a new exosome product, Infinivive MD's Cosmetic Exosome Serum.

Vitro Biopharma Announces Jack Zamora M.D. as it’s Chief Medical Advisor

The product will be distributed by InfiniveMD along with the topical stem cell serum. The product is also used as a topical application for beautification. The product is a compliment to the topical stem cell serum and will provide the customer with a more competitive price point per application depending on the particular clinic. The new Exosome product

is being marketed and sold into the clinics in the first half of 2021. We are jointly working

on a topical Daily Serum. The Exosome market is part of the billion-dollar cosmetic market in the United States. These products will also be sold offshore around the world.

Update on the Clinical Trial of Musculoskeletal Conditions in the Bahamas

This initiative broadens Vitro Biopharma's expansion into highly regulated stem cell trials in collaboration with the Nassau-based Medical Pavilion of the Bahamas (TMPB).

Home

We will now be able to extend stem cell therapy based on our novel, patent-pending AlloRx Stem Cell product to a variety of musculoskeletal conditions. These include OA of any joint, ACL/MCL tear, Achilles tendon rupture, rotator cuff injury, tennis elbow and herniated disc that are highly prevalent and have few disease-modifying options. It is important to note that many stem cell treatments now performed are problematic due to limited potency and failure to meet basic criteria of stem cells. Vitro Biopharma operates a highly regulated, FDA-compliant commercial biologics manufacturing operation for several years and is cGMP compliant, ISO 9001Certified, ISO 13485 Certified, CLIA Certified and FDA registered and BLA-compliant. All manufacturing occurs in a certified sterile clean room with extensive and advanced testing to assure the absence of contamination. Furthermore, in numerous patients treated to date by IV infusion of AlloRx Stem Cells there have been no significant adverse events. The company is partnered with Dr. Conville Brown, MD, MBBS, FACC, FESC, PhD, the founder and CEO of the Medical Pavilion of the Bahamas who is the Principal Investigator of this trial and director of its clinical administration. Dr Brown was instrumental in the establishment of the NSCEC in the Bahamas.

About the Medical Pavilion of the Bahamas: TMPB operates within a 40,000 square foot building as a partnered care specialty medical facility with 10 different centers in various areas including cardiology, cancer, clinical research and kidney disease. One of the centers is the Partners Stem Cell Centre, where the present trial will be conducted. The Partners Stem Cell Centre provides an environment to conduct stem cell research and clinical trials under the model of ''FDA rigor in a Non-FDA Jurisdiction'' TMPB employs 20 medical specialists in various fields. See http://www.tmp-bahamas.com for additional information.

The company has entered into an operating agreement with the Partner's Stem Cell Centre and expects to begin patient enrollment for the clinical trial in QI/QII of 2021 once

the Bahamas opens up without quarantine restrictions.

Due to the Corona virus pandemic the Cayman Islands closed itself and its businesses down for the majority of the quarter and next quarter, the current status is listed as locked down until Oct. 1st 2020. However, our partner reports that customers are staying on the waiting list and will return for their treatments as soon as the island opens back up. There currently is a pending backlog of over 70 patients seeking treatment which exceeds all of the treatments performed in 2019 by over 200%. We expect to see a surge in revenues from this backlog to bring back our revenue stream in the into the first half of 2021.

The Company has 11 patent applications pending in the US and foreign jurisdictions. These patents cover our AlloRx Stem Cell line and various aspects of our STEMulize stem cell activation products and processes as well as specific diagnostic tests of stem cell activity and therapeutic effectiveness. During the quarter, the Company has responded to office actions and continues to vigorously prosecute & expand its patent filings.

Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are pleased to report our activities in fighting the COVID-19 with filings of our eIND, INDs and partnership with GIOSTAR. While we are disappointed in the extraordinary events of the Corona Virus pandemic and its results on our operations, we have taken the time to advance our clinical applications, partnerships and new product development in further preparation for realized growth in 2021 as a result of these activities. In addition, with have started the intense process of organizing the company for audits and fully reporting status with the SEC targeted for January 2021.

We believe our stem cell products are distinctly superior to stem cell treatments offered in the USA. The latter usually involve use of impure products lacking validation as stem cells and containing insufficient numbers of stem cells to achieve therapeutic benefits. These are produced without regulatory oversight and have been known to cause serious adverse effects. Hence the use of highly purified and well characterized stem cells (AlloRx Stem Cells) is needed to provide safety and efficacy in regenerative medicine therapies.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10+ years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We plan to leverage our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Vitro Biopharma has supplied major biopharmaceutical firms, elite university laboratories and clinical trials worldwide with its Umbilical Cord Mesenchymal Stem Cells (AlloRx Stem Cells), and it's MSC-Grow Brand of cell culture media along with advanced stem cell diagnostic services. http://www.vitrobiopharma.com"

Sincerely yours,

James R. Musick, PhD.

President, CEO & Chairman of the Board

http://www.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends,"

"anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.

Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements.

Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick4621 Technology DriveGolden, CO 80403(303) 999-2130 x1www.vitrobiopharma.com

Vitro Diagnostics, Inc.

Quarter Ended July 31st;

Income Statement

Stem Cell Therapies and Treatments

Stem Cell Products

Other Services

Total Revenues

COGS

Gross Profit

SGA Expenses

Office Expenses

Consulting,Accounting,Legal and Banking Fees

Laboratory R&D & Quality Control

Total Operating Expenses

Net Operating Profit (Loss) EBITDA

Non Cash Depreciation and Amortization

Non Cash Stock for Services

Non Cash Interest on Shareholder Debt

Non Cash Interest on Secured Notes Payable

Net Income (Loss)

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

Vitro Diagnositics Inc.

Quarter Ended July 31st;

Balance Sheet

ASSETS

Cash

Accounts Receivable

Inventory

Notes Receivable and Prepaids

Current Assets

Fixed Assets

Intangible and other Assets

Total Assets

LIABILITIES

Trade Accounts Payable

Bank Credit Cards

Capital Lease Obligaitons

Current Liabiities

Secured Convertible Notes with discount

Capital Lease Obligations

Shareholder Accrued Comp. Payable

Shareholder Debts Payable

Long Term Liabilities

Total Liabilities

SHAREHOLDERS EQUITY

Series A Convertible Preferred

Common Stock

Paid in Capital

Treasury Stock

Retained Earnings

See original here:
Vitro Biopharma 3rd Quarter ended July 31st 2020 Financial Results of Operations - BioSpace

Read More...

Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting – Business Wire

October 4th, 2020 10:57 am

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces two presentations at the European Society for Immunodeficiencies (ESID) 2020 Meeting to be held virtually October 14-17, 2020. An oral presentation will provide an update on data from the Phase 1/2 clinical trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I). An e-poster will highlight preclinical study data on RP-L401 for Infantile Malignant Osteopetrosis (IMO).

Additional presentation details can be found below:

Oral Presentation

Title: A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1 Session Title: TreatmentPresenter: Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los AngelesSession Date: Friday, October 16, 2020Session Time: 10:45 a.m. 12:01 p.m. CESTLecture Time: 11:45 a.m. CESTLocation: Hall D

This session will be followed by a Q&A from 12:01 p.m. to 12:30 p.m. CEST

E-Poster

Title: Preclinical Efficacy and Safety of EFS.HTCIRG1-LV Supports IMO Gene Therapy Clinical Trial InitiationPresenter: Ilana Moscatelli, Ph.D., Associate Researcher, Division of Molecular Medicine and Gene Therapy, Lund University, Sweden

About Leukocyte Adhesion Deficiency-I

Severe Leukocyte Adhesion Deficiency-I (LAD-I) is a rare, autosomal recessive pediatric disease caused by mutations in the ITGB2 gene encoding for the beta-2 integrin component CD18. CD18 is a key protein that facilitates leukocyte adhesion and extravasation from blood vessels to combat infections. As a result, children with severe LAD-I (less than 2% normal expression) are often affected immediately after birth. During infancy, they suffer from recurrent life-threatening bacterial and fungal infections that respond poorly to antibiotics and require frequent hospitalizations. Children who survive infancy experience recurrent severe infections including pneumonia, gingival ulcers, necrotic skin ulcers, and septicemia. Without a successful bone marrow transplant, mortality in patients with severe LAD-I is 60-75% prior to the age of 2 and survival beyond the age of 5 is uncommon. There is a high unmet medical need for patients with severe LAD-I.

Rockets LAD-I research is made possible by a grant from the California Institute for Regenerative Medicine (Grant Number CLIN2-11480). The contents of this press release are solely the responsibility of Rocket and do not necessarily represent the official views of CIRM or any other Agency of the State of California.

About Infantile Malignant Osteopetrosis

Infantile Malignant Osteopetrosis (IMO) is a rare, severe autosomal recessive disorder caused by mutations in the TCIRG1 gene, which is critical for the process of bone resorption. Mutations in TCIRG1 interfere with the function of osteoclasts, cells which are essential for normal bone remodeling and growth, leading to skeletal malformations, including fractures and cranial deformities which cause neurologic abnormalities including vision and hearing loss. Patients often have endocrine abnormalities and progressive, frequently fatal bone marrow failure. As a result, death is common within the first decade of life. IMO has an estimated incidence of 1 in 200,000. The only treatment option currently available for IMO is an allogenic bone marrow transplant (HSCT), which allows for the restoration of bone resorption by donor-derived osteoclasts which originate from hematopoietic cells. Long-term survival rates are lower in IMO than those associated with HSCT for many other non-malignant hematologic disorders; severe HSCT-related complications are frequent. There is an urgent need for additional treatment options.

RP-L401 was in-licensed from Lund University and Medizinische Hochschule Hannover.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rockets ongoing trials, our expectations regarding when clinical trial sites will resume normal business operations, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-Q for the quarter ended June 30, 2020, filed August 5, 2020 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Read more:
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting - Business Wire

Read More...

Robert Greif named Chief Executive Officer of H-CYTE – GlobeNewswire

October 4th, 2020 10:57 am

TAMPA, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- H-CYTE, Inc.(OTCQB: HCYT), a developer of regenerative cellular therapeutics, announced today that Robert Greif has been named the companys new chief executive officer.

Robert brings decades of pharmaceutical experience to H-CYTE, having successfully taken more than a dozen products from discovery to commercialization, said Ray Monteleone, H-CYTE board member and chair of the CEO search committee. We believe he possesses the crucial skill sets necessary to oversee the potential transformation of H-CYTE into a leading biotech company, focused on innovation and meaningful patient outcomes.

I am honored to be joining the H-CYTE team to innovate and implement novel growth strategies in our biologics development, said Greif. With a focus on evidence-based medicine, it is my hope for H-CYTE to immediately begin clinical research and development of a diverse pipeline of next-generation regenerative therapeutics to meet the needs of patients with a variety of diseases and chronic health conditions.

Greif joins H-CYTE with a strong track record leading high-growth pharmaceutical and biotech businesses. Most recently, he was Chief Commercial Officer and Business Development Leader at Atox Bio, where he built the North American commercial organization in preparation for the launch of a first-in-class immunomodulator. Prior to that, he led the Commercial Operations of rEVO Biologics, an orphan disease biotechnology company. He has also held a variety of business unit and commercial leadership roles at United Health Group, Boehringer Ingelheim and Sanofi.

Greif joins H-CYTE as CEO and President effective immediately. He replaces William E. Horne, who is stepping down as CEO but will remain on the companys Board of Directors.

We are thrilled to have someone with Roberts background and experience join H-CYTE as our new CEO, especially as we transition to a biotech company, said Horne. I look forward to helping the company as a board member, assisting Robert in his transition, and watching H-CYTE thrive and prosper under his leadership.

About H-CYTE, Inc.H-CYTE is a medical biosciences company focused in the field of regenerative medicine. H-CYTEs mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions. For more information about H-CYTE, please visitwww.HCYTE.com.

Safe Harbor StatementCertain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While H-CYTE believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those outlined in H-CYTEs filings with the SEC, including but not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. H-CYTE expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACTS

H-CYTE Media RelationsSherry Yeamansyeaman@HCYTE.com214-725-4315

H-CYTE Investor RelationsJason AssadJassad@HCYTE.com678-570-6791

Read more from the original source:
Robert Greif named Chief Executive Officer of H-CYTE - GlobeNewswire

Read More...

Map of the human heart could guide treatments – Harvard Gazette

October 4th, 2020 10:57 am

Scientists have created a detailed cellular and molecular map of the healthy human heart to understand how this vital organ functions and to shed light on what goes awry in cardiovascular disease.

The work, published in Nature Sept. 24 was led by investigators at Harvard Medical School, Harvard-affiliated Brigham and Womens Hospital, the Wellcome Sanger Institute, Max Delbrck Center for Molecular Medicine (MDC) in Germany, Imperial College London and their global collaborators.

The team analyzed almost a half million individual cells to build the most extensive cell atlas of the human heart to date. The atlas shows the huge diversity of cells and reveals heart muscle cell types, cardiac protective immune cells and an intricate network of blood vessels. It also predicts how the cells communicate to keep the heart working.

The research is part of the Human Cell Atlas initiative to map every cell type in the human body. The new molecular and cellular knowledge of the heart promises to enable better understanding of heart disease and guide the development of highly individualized treatments.

The work also sets the stage for therapies based on regenerative medicine in the future, the researchers said.

Over a lifetime, the average human heart delivers more than 2 billion life-sustaining beats to the body. In doing so, it helps deliver oxygen and nutrients to cells, tissues and organs and enables the removal of carbon dioxide and waste products. Each day, the heart beats around 100,000 times with a one-way flow through four different chambers, varying speed with rest, exercise and stress. Every beat requires an exquisitely complex but perfect synchronization across various cells in different parts of heart. When this complex coordination goes bad, it can result in cardiovascular disease, the leading cause of death worldwide, killing an estimated 17.9 million people each year.

Detailing the molecular processes inside the cells of a healthy heart is critical to understanding how things go awry in heart disease. Such knowledge can lead to more precise, better treatment strategies for various forms of cardiovascular illness.

Millions of people are undergoing treatments for cardiovascular diseases. Understanding the healthy heart will help us understand interactions between cell types and cell states that can allow lifelong function and how these differ in diseases, said study co-senior author Christine Seidman, professor of medicine in the Blavatnik Institute at Harvard Medical School and a cardiovascular geneticist at Brigham and Womens.

Ultimately, these fundamental insights may suggest specific targets that can lead to individualized therapies in the future, creating personalized medicines for heart disease and improving the effectiveness of treatments for each patient, Seidman said.

This is what researchers set out to do in the new study.

The team studied nearly 500,000 individual cells and cell nuclei from six different regions of the heart obtained from 14 organ donors whose hearts were healthy but unsuitable for transplantation.

Using a combination of single-cell analysis, machine learning and imaging techniques, the team could see exactly which genes were switched on and off in each cell.

The researchers discovered major differences in the cells in different areas of the heart. They also observed that each area of the heart had specific subsets of cells a finding that points to different developmental origins and suggests that these cells would respond differently to treatments.

This project marks the beginning of new understandings into how the heart is built from single cells, many with different cell states, said study co-first author Daniel Reichart, research fellow in genetics at Harvard Medical School. With knowledge of the regional differences throughout the heart, we can begin to consider the effects of age, exercise and disease and help push the field of cardiology toward the era of precision medicine.

This is the first time anyone has looked at the single cells of the human heart at this scale, which has only become possible with large-scale single-cell sequencing, said Norbert Hbner, co-senior author and professor at Max Delbrck Center for Molecular Medicine. This study shows the power of single-cell genomics and international collaboration, he added. Knowledge of the full range of cardiac cells and their gene activity is a fundamental necessity to understand how the heart functions and to start to unravel how it responds to stress and disease.

As part of this study, the researchers also looked at blood vessels running through the heart in unprecedented detail. The atlas showed how the cells in these veins and arteries are adapted to the different pressures and locations and how this could help researchers understand what goes wrong in blood vessels during coronary heart disease.

Our international effort provides an invaluable set of information to the scientific community by illuminating the cellular and molecular details of cardiac cells that work together to pump blood around the body, said co-senior author Michela Noseda of Imperial College, London. We mapped the cardiac cells that can be potentially infected by SARS-CoV-2 and found that specialized cells of the small blood vessels are also virus targets, she said. Our datasets are a goldmine of information to understand subtleties of heart disease.

The researchers also focused on understanding cardiac repair, looking at how the immune cells interact and communicate with other cells in the healthy heart and how this differs from skeletal muscle.

Further research will include investigating whether any heart cells could be induced to repair themselves.

This great collaborative effort is part of the global Human Cell Atlas initiative to create a Google map of the human body, said Sarah Teichmann of the Wellcome Sanger Institute, co-senior author of the study and co-chair of the Human Cell Atlas Organising Committee.

Openly available to researchers worldwide, the Heart Cell Atlas is a fantastic resource, which will lead to new understanding of heart health and disease, new treatments and potentially even finding ways of regenerating damaged heart tissue, she said.

This study was supported by the British Heart Foundation, European Research Council, Federal Ministry of Education and Research of Germany, Deutsches Zentrum fr Herz-Kreislaufforschung e.V., Leducq Fondation, German Research Foundation, Chinese Council Scholarship, the Alexander von Humboldt Foundation, EMBO, Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Alberta Innovates, Chan Zuckerberg Initiative, Wellcome Sanger Institute, Wellcome, U.S. National Institutes of Health and Howard Hughes Medical Institute.

Jonathan Seidman, the Henrietta B. and Frederick H. Bugher Foundation Professor of Genetics in the Blavatnik Institute at HMS, is also co-senior author. Monika Litviukov and Carlos Talavera-Lpez of the Sanger Institute and Henrike Maatz of the Max Delbrck Center are co-first authors with David Reichart.

Here is the original post:
Map of the human heart could guide treatments - Harvard Gazette

Read More...

Cancer Vaccines: The Fourth Pillar of Anti-Cancer Therapy? – JD Supra

October 4th, 2020 10:57 am

[co-authors: Dan Meckley, Preston Tran, and Heather Hatcher, Ph.D.]

Photo by National Cancer Institute on Unsplash

Innovative technologies are being deployed to address the Western worlds major killer: cancer. Traditionally, cancer treatment has included surgery, chemotherapy, and radiation, but recently, the development of targeted immunotherapies such as monoclonal antibodies and immune checkpoint inhibitors (e.g., PD-1, PD-L1 and CTLA-4 inhibitors) are showing considerable promise in immunooncology.

The fields of immunology and oncology have been linked since the late 19th century, when studies showed that killed and denatured bacteria injected into sites of sarcoma (a tumor that starts in the bone or muscle) resulted in tumor shrinkage. The intersection between immune surveillance and tumor biology has led to broad therapeutic advances, including the search for a cancer vaccine.

Traditional prophylactic vaccines work to prevent disease by preparing the bodys immune system against a pathogenic infection such as influenza or polio. Over the last decade, the US Food and Drug Administration (FDA) has approved prophylactic vaccines that prevent development of cancer by protecting against cancer-causing pathogens such as human papillomavirus (HPV) (GARDASIL 9; Merck Sharp & Dohme Corp., Whitehouse Station, NJ) and hepatitis B virus (HEPLISAV-B; Dynavax Technologies Corp., Emeryville, CA).

A cancer vaccine is a therapeutic vaccine that targets pre-existing tumors in cancer patients who have a fundamentally different immune response relative to that of healthy individuals. Cancer is characterized by an accumulation of genetic alterations, and every tumor has its own unique composition of mutations and novel surface antigens, or neo-antigens, with only a small fraction shared between patients. Not surprisingly, therapeutic vaccines have been challenging to develop; however, tumor neo-antigens present an antigenic target for pharmaceutical companies to design and develop cancer vaccines.

Within the past several years, there has been an explosion in early-stage clinical activity in gene-modified and cell-based immunooncology, which now encompasses about 58% of Phase I trials. The FDAs Center for Biologics Evaluation and Research (CBER) provided sponsors with guidance on Clinical Considerations for Therapeutic Cancer Vaccines (October 2011) to determine optimal dosing, potential biological and clinical activity, and safety profile during early phase clinical trials, as well as endpoint selection in late phase clinical trials to support a subsequent Biologics License Application (BLA) for marketing approval. Many trials have shown potent therapeutic responses in a proportion of patients with late stage cancer, but it has been rare for trials to obtain more than a 510% partial or complete response. However, this limited success has not lessened the enthusiasm for development of potential cancer vaccines. In 2019, there were nearly 700 oncology clinical trials utilizing specific regenerative medicine and advanced therapy technologies to treat leukemia, lymphoma, and cancers of the brain, breast, bladder, cervix, colon, esophagus, ovaries, pancreas and others (ARM 2019 Annual Report, https://alliancerm.org/sector-report/2019-annual-report/). The 2010 FDA approval of the first cancer vaccine (Provenge (sipuleucel-T); Dendreon Corp., Seattle, WA), was supported by clinical trials showing that the vaccine prolongs survival in patients with metastatic, castration-resistant prostate cancer, though the effect was modest. In 2015, the FDA approved a therapeutic cancer vaccine for the treatment of advanced melanoma (IMLYGIC or T-VEC, talimogene laherparepvec; Amgen, Thousand Oaks, CA).

Despite the challenges, each translation of cancer vaccines to the clinical setting has yielded a deeper understanding of the immunologic response produced by cancer.

Several platforms for cancer vaccination are being tested, including peptides, proteins, antigen presenting cells, tumor cells, and viral vectors. Prior clinical trials have shown that cancer vaccines are well tolerated, target tumor neo-antigens and induce antigen cascade. Current trials seek to improve cancer vaccine efficacy either by targeting novel tumor antigens or employing vaccines in combination with other therapeutic approaches. Additionally, provisions in the 21st Century Cures Act have allowed the FDA to use an accelerated approval pathway for cancer vaccines that have been designated as regenerative medicine advanced therapy (RMAT).

Cancer vaccination comprises an array of approaches that seek to generate, amplify, or skew (or a combination thereof) antitumor immunity. Cancer immunotherapy may ultimately establish its position as the fourth pillar of anti-cancer therapy, complementing surgery, chemotherapy, and radiation.

[View source.]

See the original post here:
Cancer Vaccines: The Fourth Pillar of Anti-Cancer Therapy? - JD Supra

Read More...

Purdue Veterinary Medicine Receives 2020 Health Professions Higher Education Excellence in Diversity (HEED) Award – Purdue Veterinary News

October 4th, 2020 10:56 am

Friday, October 2, 2020

The Purdue University College of Veterinary Medicine is being honored today as a recipient of the 2020 Health Professions Higher Education Excellence in Diversity (HEED) Award from INSIGHT Into Diversity magazine, the oldest and largest diversity-focused publication in higher education. Presented annually, the national Health Professions HEED Award recognizes U.S. colleges and universities that demonstrate an outstanding commitment to diversity and inclusion. Insight Into Diversity magazine made the announcement today (Friday, October 2). As an award recipient, the college will be featured, along with 45 other recipients, in the December 2020 issue of the magazine.

Dean Willie Reed said the award is a great reflection of the colleges deep and abiding commitment to diversity, equity, and inclusion. This award makes an important statement about the way in which our college doesnt just talk about diversity and inclusion, but lives it, Dean Reed said. The Purdue University College of Veterinary Medicine is playing a leadership role nationally with model initiatives that advance diversity and inclusion in veterinary medicine.We are working diligently to make measurable progress as a college and as a profession in being truly welcoming and supportive of everyone and this award documents that fact.

This is the second year Purdue Veterinary Medicine has been named as a Health Professions HEED Award recipient. PVM continues to raise the bar in diversity, equity, and inclusion through its innovative programming and leadership, said Dr. Latonia Craig, the colleges assistant dean for inclusive excellence. We are so thrilled for PVM to receive this award. Diversity, Equity, and Inclusion lie at the heart of PVMs mission. We have a supportive college community that makes every effort to ensure we bring our core values to life daily. This work is not easy, but we do it because thats just who we are, Dr. Craig explained. You can have diversity without inclusion, but at PVM, we strive to create an environment that welcomes and includes each student, faculty, and staff member. We hope that our efforts will inspire others to engage in this work in the best way they know how.

INSIGHT Into Diversity magazine selected Purdue Veterinary Medicine for the award because of its multiple diversity and inclusion initiatives. In February, the college launched its five-year diversity strategic plan, which continues to receive praise for its thoroughness and commitment to inclusive excellence. PVMs role in advancing diversity, equity, and inclusion in veterinary medicine is long-standing. Award-winning programs such as Vet Up!, led by Dr. Craig, and This is How We Role, led by Dr. Sandra San Miguel, associate dean for engagement, each received INSIGHT Into Diversity magazines Inspiring Programs in STEM Award in 2019 and 2020, respectively. Other programs include PVMs new and popular virtual Learning Cafs, a monthly series of 50-minute critical conversations surrounding diverse topics chosen by the PVM community.

The HEED Award process consists of a comprehensive and rigorous application that includes questions relating to the recruitment and retention of students and employees and best practices for both, continued leadership support for diversity, and other aspects of campus diversity and inclusion, said Lenore Pearlstein, publisher of INSIGHT Into Diversity magazine. We take a detailed approach to reviewing each application in deciding who will be named a HEED Award recipient. Our standards are high, and we look for institutions where diversity and inclusion are woven into the work being done every day across their campus.

The other recipients of the 2020 Health Professions HEED Award include three other veterinary schools:

Click here for more information about the 2020 Health Professions HEED Award.

Writer(s): Kevin Doerr | pvmnews@purdue.edu

Read the rest here:
Purdue Veterinary Medicine Receives 2020 Health Professions Higher Education Excellence in Diversity (HEED) Award - Purdue Veterinary News

Read More...

Vice President, Division of Agriculture, Forestry, and Veterinary Medicine job with Mississippi State University | 290163 – The Chronicle of Higher…

October 4th, 2020 10:56 am

Mississippi State University seeks to hire a Vice President forthe Division of Agriculture, Forestry, and Veterinary Medicine(DAFVM).

Mississippi State University (MSU) represents the highestlevel of research activity for doctorate-granting institutions andis designated by the Carnegie Foundation as an R1-Very HighResearch Activity University. Also, a National ScienceFoundation Top 100 research University, MSU shelters a chapter ofPhi Beta Kappa, the nations oldest and most prestigious honorsociety, and values the talents of our distinguished faculty,staff, and student scholars. With over 22,000 students and4,600 faculty and staff, MSU is located in Starkville, MS. Here, aculture of inclusion is fostered and were driven each day to makea difference at the local, state, regional, national and globallevels. We invite you to join MSU as we continue our momentumin research, teaching, and service.

DAFVM consists of six major units: The College of Agricultureand Life Sciences (CALS), The College of Forest Resources (CFR),the College of Veterinary Medicine (CVM), the MississippiAgricultural and Forestry Experiment Station (MAFES), the Forestand Wildlife Research Center (FWRC) and the MSU Extension Service(MSUES.) These unit heads report to the Vice President. TheDeans of the three academic colleges report jointly to theUniversity's Provost and Executive Vice President of AcademicAffairs. The Heads of some specialized research centers andinstitutes within the Division may also report to additional vicepresidents. DAFVM conducts teaching, research, extensionprogramming, and service on the University's main campus andthrough four research and extension centers, 16 branch stations,four CVM diagnostic labs, and Extension offices in all 82 countiesof Mississippi. Annual expenditures by units in the Divisionare normally at or above $200 million. The National ScienceFoundation has ranked MSU #11 in Research and Developmentexpenditures in Agriculture Sciences, Natural Resources andConservation.

Duties and Responsibilities:

The Vice President serves along with the other vice presidentsas a member of the University's senior management team providingvisionary leadership for planning, budgeting, and resourcedevelopment. The Vice President is also responsible for thedevelopment of strategic goals for DAFVM and evaluating programs,faculty, and staff within DAFVM. The Vice President developsand maintains productive relationships with agriculture andforestry producers; industry constituents; federal, state, andlocal government agencies; and organizations and associations thatare concerned with agriculture and natural resources, families andyouth, and community development. The Vice President promotesdiversity within DAFVM with respect to faculty, staff, and studentsand fosters a sense of common purpose while serving as an advocatefor DAFVM to its constituencies and as a spokesperson foragriculture and natural resources both regionally andnationally. The Vice President worksclosely with the Provost and Executive Vice President regarding theacademic mission within DAFVM, and the Vice President for Researchand Economic Development regarding the research missions withinDAFVM. The Vice President is expected to take a leadershiprole in strategic initiatives that project the University withinMississippi, nationally, and globally.

Qualifications:

Candidates should have an earned doctorate in an appropriatearea in agriculture, natural resources, or a related field withcredentials and experience to qualify for the rank of professorwith tenure in a discipline within the Division. He/She mustdemonstrate a strong recognition of and commitment to Mississippisagricultural roots. The candidate must have a demonstratedability to work effectively with the academic, agricultural naturalresources and business communities, industry constituents, andfederal partners. A record of successful administrativeleadership and achievement, including the acquisition of public andprivate resources to develop and expand strong agriculturalprograms, is also required. Candidates should havesubstantial experience with a minimum of four years of significantadministrative experience. The successful candidate shouldhave a thorough familiarity and understanding of the land-grantsystem and the interrelationship between the teaching, research andextension programs. The candidate must possess the vision andexperience necessary to lead a complex organization in developingand enhancing its research mission in service to the state, region,and nation as a premier research leader. He/She must alsodemonstrate familiarity with the land-grant system and foster thedesire to promote excellence throughout the division and theuniversity.

Salary and Benefits:

Salary commensurate with education, experience; competitivebenefits.

Application Procedure:

Qualified candidates are requested to submit a letter ofapplication that should include a statement of administrativephilosophy emphasizing their ability to foster effective academicprograms, expand research, and promote extension activities: anexpression of his/her commitment to growth of the divisionsprograms and student enrollment. Please include a completecurriculum vitae, including the names, addresses and phone/emailfor five references. Initial nominations and inquiries willbe kept confidential; references will be contacted only uponapproval by the candidate. Application review will beginDecember 1, 2020, and continue until a successful candidate isidentified. Nominations of outstanding potential candidatesare welcome.

Nomination applications and/or inquires should be sent to:

David R. Shaw, Provost and Executive Vice PresidentMississippi State UniversityOffice of the Provost and Executive Vice President3500 Lee Hall262 Lee Blvd.Mississippi State, MS 39762david.shaw@msstate.eduPhone: 662-325-3742

Mississippi State University is an equal opportunityinstitution. Discrimination in university employment, programs, oractivities based on race, color, ethnicity, sex, pregnancy,religion, national origin, disability, age, sexual orientation,genetic information, status as a U.S veteran, or any other statusprotected by applicable law is prohibited. Questions about equalopportunity programs or compliance should be directed to the Officeof Compliance and Integrity, 56 Morgan Avenue, P.O.6044,Mississippi State, MS 39762. (662) 325-5839.

Mississippi State University is an equal opportunityinstitution. Discrimination in university employment,programs, or activities based on race, color, ethnicity, sex,pregnancy, religion, national origin, disability, age, sexualorientation, genetic information, status as a U.S veteran, or anyother status protected by applicable law is prohibited.Questions about equal opportunity programs or compliance should bedirected to the Office of Compliance and Integrity, 56 MorganAvenue, P.O.6044, Mississippi State, MS 39762. (662)325-5839.

Continue reading here:
Vice President, Division of Agriculture, Forestry, and Veterinary Medicine job with Mississippi State University | 290163 - The Chronicle of Higher...

Read More...

Merck Animal Health Honors Dr. Gordon Atkins as Mentor of the Year – Hoard’s Dairyman

October 4th, 2020 10:56 am

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) and the American Association of Bovine Practitioners (AABP) presented Gordon Atkins, D.V.M., with the Mentor of the Year Award at the AABP Annual Conference. This award, which is issued annually, recognizes an individual who has played a role in educating, supporting and advancing the careers of future bovine veterinarians.

Dr. Atkins has mentored countless students, inspiring them to pursue their interest in bovine medicine, said Justin Welsh, D.V.M., executive director, livestock technical services for Merck Animal Health. He cares about every student, goes the extra mile to help them achieve their goals and leaves a tremendous impact on their lives as well as the animals in their care.

Dr. Atkins grew up on a dairy farm in the Calgary, Canada area, received his D.V.M., with distinction, from the Western College of Veterinary Medicine in 1973 and has been practicing veterinary medicine in the Calgary area since graduation. In 2008, Dr. Atkins joined the University of Calgary Faculty of Veterinary Medicine (UCVM) as senior instructor, clinical skills, and in 2015 was one of only a few faculty members to be given the inaugural designation of teaching professor.

Mentoring and teaching come easily to Dr. Atkins, as he simply leads by example: first one at the clinic in the morning, last one to leave, a constant professional, said Troy Drake, D.V.M., owner of HerdTrax Inc., Kathyrn, Alberta, who was hired by Dr. Atkins veterinary practice as a third-year veterinary student and subsequently an associate veterinarian. His contributions go well beyond bovine surgery and medicine. He has made his students, fellow veterinarians, the veterinary profession, cattle producers, and the entire livestock industry better off because of his passion for and mentorship within veterinary medicine.

Dr. Atkins has played a large role in the delivery of the universitys D.V.M. program, according to John Kastelic, D.V.M, Ph.D, professor and head, Department of Production Animal Health, University of Calgary. He has 300 to 400 hours of contact time spent with students annually for lectures and laboratories, said Kastelic. He draws on his decades of practice experience and huge library of photographs and videos to convey his message. He consistently receives extremely high rankings from veterinary students in teaching assessments.

Dr. Atkins has won many awards for his contributions to veterinary medicine, including the Canadian Veterinary Medical Association of the Year Award, Carl J. Norden Distinguished Teacher Award and a University of Calgary Union Teaching Excellence Award through nomination by veterinary students. Perhaps the most exceptional accolade is his personal commitment and dedication to each student, said Megan Dick, a student in the UCVM class of 2020.

Fellow student Rae-Leigh Pederzolli said Dr. Atkins is one of the most involved professors and mentors that a student could ask for, and that didnt stop after she left school. As a new graduate, I have called Dr. Atkins late at night and early in the morning only to hear happiness in his voice to hear from me while wondering what case was presented to me that day, said Pederzolli. I am grateful that he hasnt retired yet, but even then his phone will always be on.

Fred Gingrich II, D.V.M., executive director of AABP, added, Dr. Atkins is known by students and colleagues for his enthusiasm. He strives to ensure every student is grounded with practical knowledge and is confident in their skills. He is a most deserving candidate to join the long list of other Mentor of the Year recipients.

Dr. Atkins is an active member of numerous veterinary organizations, including AABP, where he served as president in 1992 and received the AABP Bovine Practitioner of the Year Award in 1988. He is an Honor Roll member of AABP and the 14th recipient of the Mentor of the Year Award, which was established in 2007.

About Merck Animal Health

For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the worlds most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit http://www.merck-animal-health.comor connect with us on LinkedIn,Facebookand Twitter at @MerckAH.

Originally posted here:
Merck Animal Health Honors Dr. Gordon Atkins as Mentor of the Year - Hoard's Dairyman

Read More...

Penn. clinic named AAHA-Accredited Practice of the Year – VeterinaryPracticeNews.com

October 4th, 2020 10:56 am

Dedication, hard work, and a commitment to positive workplace culture are among the top qualities the American Animal Hospital Association (AAHA) values in its accredited practices.

To that, Manheim Pike Veterinary Hospital in Lancaster, Penn., has been named the 2020 AAHA-Accredited Practice of the Year. The practice was presented with the honor virtually during Connexity by AAHA, the associations annual conference, which was hosted online Oct. 1.

We were very impressed by the dedication to positive workplace culture at Manheim Pike Veterinary Hospital, says the associations deputy chief executive officer, Janice Trumpeter, DVM. At AAHA, we strongly believe in continuous improvement and development of healthy practice environments, in order to better serve patients and clients.

The award recognizes the outstanding achievements of accredited veterinary practice teams and celebrates ongoing advancements in veterinary medicine. Teams are evaluated based on their most recent accreditation score, mission and vision, practice team composition, continuing education (CE) and training, and community service.

Other finalists this year include:

The rest is here:
Penn. clinic named AAHA-Accredited Practice of the Year - VeterinaryPracticeNews.com

Read More...

Page 362«..1020..361362363364..370380..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick